ArriVent BioPharma, Inc. Common Stock (AVBP)vsAstraZeneca PLC (AZN)
AVBP
ArriVent BioPharma, Inc. Common Stock
$15.95
+1.40%
HEALTHCARE · Cap: $884.58M
AZN
AstraZeneca PLC
$169.51
+2.88%
HEALTHCARE · Cap: $263.78B
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 62/100 (C+).
AVBP
Avoid26
out of 100
Grade: F
AZN
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AVBP.
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$169.51
$25.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AVBP
The strongest argument for AVBP centers on Debt/Equity, Altman Z-Score, Price/Book.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bear Case : AVBP
The primary concerns for AVBP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
AVBP profiles as a value stock while AZN is a mature play — different risk/reward profiles.
AVBP carries more volatility with a beta of 1.35 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 26/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ArriVent BioPharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
ArriVent BioPharma, Inc. (AVBP) is a dynamic biopharmaceutical company dedicated to developing pioneering therapies that address critical unmet needs in oncology and autoimmune diseases. The company harnesses proprietary technologies and a strong scientific foundation to create a promising pipeline aimed at enhancing patient outcomes. Positioned in high-growth sectors of the biopharma industry, ArriVent presents an appealing investment opportunity for institutional investors looking to engage in impactful healthcare innovations with substantial market potential.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?